Polymyalgia Rheumatica Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

Polymyalgia Rheumatica Market  Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

“Polymyalgia Rheumatica Market”
DelveInsight’s “Polymyalgia Rheumatica Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Polymyalgia Rheumatica, historical and forecasted epidemiology as well as the Polymyalgia Rheumatica market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s Polymyalgia Rheumatica Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of Polymyalgia Rheumatica, historical and forecasted epidemiology as well as the Polymyalgia Rheumatica market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Polymyalgia Rheumatica market report provides current treatment practices, emerging drugs, Polymyalgia Rheumatica market share of the individual therapies, current and forecasted Polymyalgia Rheumatica market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Polymyalgia Rheumatica treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Polymyalgia Rheumatica market


Some of the key facts of the Polymyalgia Rheumatica Market Report:

  • In patients with PMR, the synovial membranes and bursae that line and lubricate the joints become inflamed, causing pain and discomfort. Unlike in some other inflammatory diseases, there is no associated permanent damage to the joints or the muscles.
  • According to Nothnagel T, Leeb, the gene(s) that could be responsible for PMR have not been definitively identified. The HLA-DRB104 and HLA-DRB01 alleles have both been found to have a possible link to PMR and GCA although this remains controversial.


Key benefits of the Polymyalgia Rheumatica Market report:


  • The report covers the descriptive overview of Polymyalgia Rheumatica, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Polymyalgia Rheumatica epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Polymyalgia Rheumatica is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Polymyalgia Rheumatica market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Polymyalgia Rheumatica market


Got queries? Click here to know more about the Polymyalgia Rheumatica Market Landscape 

Polymyalgia Rheumatica Overview

Polymyalgia rheumatic (PMR) is a rare inflammatory disease characterized by muscle pain (myalgia), stiffness, and additional generalized systemic symptoms such as fatigue, low-grade fever, and/or a general feeling of ill health (malaise). PMR can be a relatively benign condition that is extremely responsive to treatment. In some rare cases, permanent muscle weakness, degeneration and loss (atrophy) of muscle mass, and disability may occur

The diagnosis of PMR may be confirmed by a thorough clinical examination, including detailed patient history and specialized blood testing that demonstrates an abnormally elevated sedimentation rate. Other substances in the blood, such as serum albumin, globulins, and fibrinogen, may also be elevated

Nonsteroidal anti-inflammatory drugs (NSAIDs) may be used to treat those people with PMR who do not have vascular symptoms or signs (e.g., recurring headaches indicative of giant cell arteritis). Some affected individuals respond well to treatment with aspirin, which relieves pain and reduces inflammation

Polymyalgia Rheumatica Epidemiological Insights:

  • Polymyalgia rheumatic (PMR) is a rheumatic inflammatory disorder that has an unknown cause. It causes inflammation of the large muscles of the body and can be accompanied by systematic symptoms including malaise, fatigue, fever, and weight loss.
  • According to Dasgupta B ‘, et al polymyalgia rheumatic occurs worldwide, the highest incidence is seen in Scandinavian countries and in people of northern European descent. In the United States, the lifetime risk of developing PMR is estimated at 2.43% for women and 1.66% for men. The lowest incidence rates occur at the more southern European countries like Italy, and Spain.
  • According to Duncan et al. the estimated prevalence of PMR, in the United States, is 1 in 133 people over the age of 50 years. The incidence of PMR and GCA increases with age, with a peak in those 70–80 years of age. 
  • According to Crowson et al,’  women accounted for 65 to 75% of patients. Polymyalgia rheumatic occurs at a frequency that is 3 to 10 times that of giant-cell arthritis
  • A study by E. Machado et al. of biopsy-proven GCA demonstrated an average annual incidence and prevalence of 17 and 223, respectively per 100,000 population aged 50 years or more cases in Scandinavian countries and northwestern Spain.
  • A Japanese national survey gave the prevalence for GCA, in patients aged 50 years and older, of 1.47 per 100,000 population, a 100-fold less than the prevalence quoted in a western population.

Polymyalgia Rheumatica Market Epidemiological Segmentation

  • Total Polymyalgia Rheumatica  prevalence
  • Polymyalgia Rheumatica gender-specific prevalence 
  • Polymyalgia Rheumatica prevelant cases based on clinical manifestation.
  • Polymyalgia Rheumatica  total diagnosed cases 

Polymyalgia Rheumatica Market Outlook 

The Polymyalgia Rheumatica market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Polymyalgia Rheumatica market trends by analyzing the impact of current Polymyalgia Rheumatica therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Polymyalgia Rheumatica market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Polymyalgia Rheumatica market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 According to DelveInsight, the Polymyalgia Rheumatica market in 7MM is expected to witness a major change in the study period 2019-2032.

 Learn more by requesting for sample @ Polymyalgia Rheumatica Market Landscape

Polymyalgia Rheumatica Key Companies  

  • Roche
  • Bristol Myers Squibb
  • Eli-Lilly
  • and many more 

Polymyalgia Rheumatica Therapies 

  • Tocilizumab
  • Abatacept
  • Baricitinib
  • And others

Table of Contents

  • Key Insights 
  • Report Introduction 
  • Executive Summary of Polymyalgia Rheumatica   Market 
  • Disease Background and Overview
  • Epidemiology and patient population
  • The United States 
  • EU 5
  • Polymyalgia Rheumatica   Market   Emerging Therapies
  • Polymyalgia Rheumatica   Market  Market Outlook
  • Market Access and Reimbursement of Therapies
  • Appendix
  • Polymyalgia Rheumatica   Market  Report Methodology
  • DelveInsight Capabilities
  • Disclaimer

Click here to read more about Polymyalgia Rheumatica Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/